3Rajpurkar M, Chitlur M, Reeht M, et al. Use of recombinant activated factor & in patients with Glanzmann ' s thrombasthenia: a review of the literature[J]. Haemophilia, 2014,20(4) :464-471.
4Nurden AT, Pillois X, Wilcox DA. Glanzmann thrombasthenia., state of the art and future directions [J]. Semin Thromb Hemost,2013,39(6) :642-655.
4GEORGE J N,CAEN J P,NURDEN A T. Glanz-mann thrombasthenia : The spectrum of clinical dis-ease[J]. Blood, 1990,75 :1383 —1395.
5CATTANEO M. Light transmission aggregometryand ATP release for the diagnostic assessment ofplatelet function [J]. Semin Thromb Hemost, 2009,35:158 — 167.
7ITO K, YOSHIDA H,HATOYAMA H’et al. Anti-body removal therapy used successfully at delivery ofa pregnant patient with Glanzmanrfs thrombastheniaand multiple anti-platelet antibodies [J]. Vox Sang,1991,61:40-46.
8POON M C,CrOIRON R’VON DEPKA M,et al. In-ternational data collection on recombinant factor Vilaand congenital platelet disorders study group : prophy-lactic and therapeutic recombinant factor Vila admin-istration to patients with Glanzmann's thrombasthe-nia :results of an international survey [J]. J ThrombHaemost,2004,2:1096 —1103.
